Recent news
and insights
Covid-19: implications for medical oncologists
A valuable and personal perspective from Italy by Dr. Fotios Loupakis
Experts Forum on DDR and PARP inhibition in Tokyo and Singapore, January 2020
Experts Forum on DDR and PARP inhibition in Tokyo and Singapore
NTRK gene fusions, TRK inhibitors and testing approaches BluePrint
A variety of topics are covered including, overview of gene fusions and role as oncogenic drivers, detection approaches available, NTRK family and NTRK gene fusions...
The role of PARP inhibition in clinical practice
Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive, free to access e-learning course.
Overview of cancers with NTRK Gene Fusions and importance of testing
Information on TRK fusion proteins as a potential therapeutic target for selected patients across multiple tumour types.
Management of Skin Toxicities from MKI Therapies (Recently Updated)
Comprehensive resource providing information on the management of multikinase inhibitor-associated skin toxicities.
The CONNECTs News
-
NET CONNECT Update from ENETS 2020
-
Treating mCRPC patients who have progressed on AR-directed therapy
-
GI CONNECT e-learning on the impact of key CRC data on sequential clinical practice
-
SARCOMA CONNECT: Highlights from ESMO Sarcoma and GIST 2020
-
LYMPHOMA CONNECT Experts Knowledge Share ASH 2019
-
Event 1: Bambino Gesù Children’s Hospital, January 2020
-
HCC CONNECT e-learning with important new data on treatment sequencing in advanced HCC
-
NTRK gene fusions, TRK inhibitors and testing approaches BluePrint
-
The GUIDE Communication Framework
-
Update from ESMO 2019